FCG Investment Co Sells 205 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

FCG Investment Co trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 20.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 819 shares of the biopharmaceutical company’s stock after selling 205 shares during the period. FCG Investment Co’s holdings in Regeneron Pharmaceuticals were worth $583,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Avior Wealth Management LLC boosted its stake in Regeneron Pharmaceuticals by 29.1% during the 4th quarter. Avior Wealth Management LLC now owns 1,190 shares of the biopharmaceutical company’s stock valued at $848,000 after purchasing an additional 268 shares during the period. Traynor Capital Management Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 10.7% during the fourth quarter. Traynor Capital Management Inc. now owns 24,790 shares of the biopharmaceutical company’s stock worth $17,659,000 after buying an additional 2,400 shares during the last quarter. Hudson Capital Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 7.8% in the fourth quarter. Hudson Capital Management LLC now owns 4,961 shares of the biopharmaceutical company’s stock valued at $3,534,000 after acquiring an additional 357 shares during the period. Janney Montgomery Scott LLC grew its stake in shares of Regeneron Pharmaceuticals by 21.8% in the fourth quarter. Janney Montgomery Scott LLC now owns 23,066 shares of the biopharmaceutical company’s stock worth $16,431,000 after acquiring an additional 4,130 shares during the last quarter. Finally, BDF Gestion acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $1,956,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on REGN. Evercore ISI reduced their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Sanford C. Bernstein reduced their target price on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Piper Sandler decreased their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Oppenheimer cut their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Finally, Morgan Stanley decreased their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $1,015.38.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $694.64 on Friday. The business’s fifty day moving average is $730.57 and its two-hundred day moving average is $942.10. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The firm has a market cap of $76.33 billion, a P/E ratio of 17.19, a P/E/G ratio of 1.59 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 52 week low of $666.25 and a 52 week high of $1,211.20.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.